ArticleFrontiers in aging neuroscience2026
Selective amygdala subregional atrophy in Parkinson's disease: from subjective cognitive decline to mild cognitive impairment.
Article in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cognitive impairment is a common and disabling non-motor feature of Parkinson's disease (PD). Subjective cognitive decline (SCD) has been proposed as an early clinical stage of cognitive dysfunction in PD; however, its neuroanatomical correlates remain poorly defined. The amygdala is an early target of PD-related pathology, yet subregional alterations across different cognitive stages of PD have not been systematically examined. Objective: To characterize amygdala subregional atrophy patterns across the cognitive continuum of PD, specifically distinguishing between subjective cognitive decline and mild cognitive impairment (MCI). Methods: High-resolution T1-weighted MRI was acquired in 68 PD patients classified as cognitively normal (PD-NC, Results: Compared to controls and cognitively normal PD patients, the PD-MCI group exhibited significant atrophy specifically in the medial and cortical nuclei of the amygdala. Volumes of the medial and cortical nuclei were positively correlated with global cognitive performance and visuospatial/executive function. Multinomial logistic regression identified larger medial amygdala volume as an independent correlate of cognitive preservation in PD. Conclusion: Cognitive impairment in PD is associated with selective atrophy of specific amygdala subregions. In contrast, PD-SCD involves no detectable amygdala atrophy, suggesting it represents a structurally preserved stage preceding overt neurodegeneration. These findings suggest that PD-SCD represents a structurally preserved stage and highlight amygdala subregional volumetry as a potential biomarker for cognitive impairment in PD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.